Published in Cancer Res on December 15, 2001
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther (2009) 1.22
DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol (2010) 1.12
Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol Lett (2007) 1.09
Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology (2012) 1.08
Cancer vaccines. BMJ (2015) 1.07
Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol (2006) 1.04
AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients. J Immunother (2007) 0.96
Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J Gene Med (2007) 0.96
DNA vaccines, electroporation and their applications in cancer treatment. Hum Vaccin Immunother (2015) 0.89
Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients. Clin Dev Immunol (2011) 0.83
Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo. Int J Oncol (2011) 0.81
Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med (2014) 0.81
Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity. J Transl Med (2010) 0.80
Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology (2014) 0.80
Secondary anchor substitutions in an HLA-A*0201-restricted T-cell epitope derived from Her-2/neu. Mol Immunol (2006) 0.79
Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects. Immunotherapy (2014) 0.78
Tumor vaccine against recurrence of hepatocellular carcinoma. World J Gastroenterol (2005) 0.78
Antitumor immunity induced by DNA vaccine encoding alpha-fetoprotein/heat shock protein 70. World J Gastroenterol (2004) 0.77
Antitumor immunopreventive effect in mice induced by DNA vaccine encoding a fusion protein of alpha-fetoprotein and CTLA4. World J Gastroenterol (2004) 0.75
Recombinant heat shock protein 70 functional peptide and alpha-fetoprotein epitope peptide vaccine elicits specific anti-tumor immunity. Oncotarget (2016) 0.75
JAK2 inhibitor combined with DC-activated AFP-specific T-cells enhances antitumor function in a Fas/FasL signal-independent pathway. Onco Targets Ther (2016) 0.75
Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg (1992) 9.97
A herpes simplex virus transcript abundant in latently infected neurons is dispensable for establishment of the latent state. Virology (1988) 3.11
IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol (1989) 2.86
Factors influencing the immune response. I. Effects of the physical state of the antigen and of lymphoreticular cell proliferation on the response to intravenous injection of bovine serum albumin in rabbits. Clin Exp Immunol (1967) 1.85
T cell assays and MIATA: the essential minimum for maximum impact. Immunity (2012) 1.74
Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia (2002) 1.71
Tumour growth, phagocytic activity and antibody response in Corynebacterium parvum-treated mice. Clin Exp Immunol (1974) 1.69
Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells. J Natl Cancer Inst (1999) 1.69
Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys (2000) 1.69
Chronic lymphocytic leukemia and the central nervous system: a clinical and pathological study. Neurology (1996) 1.66
The regulation of the human tumor necrosis factor alpha promoter region in macrophage, T cell, and B cell lines. J Biol Chem (1992) 1.65
Biologically effective dose distribution based on the linear quadratic model and its clinical relevance. Int J Radiat Oncol Biol Phys (1995) 1.63
Dietary modulation of omega-3/omega-6 polyunsaturated fatty acid ratios in patients with breast cancer. J Natl Cancer Inst (1997) 1.62
Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line. J Exp Med (1989) 1.62
Increased phagocytic cell activity and anaemia in Corynebacterium parvum treated mice. Br J Exp Pathol (1974) 1.53
In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum Gene Ther (1997) 1.53
Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest (2002) 1.50
Alteration in myelin-associated proteins following spinal cord irradiation in guinea pigs. Int J Radiat Oncol Biol Phys (1992) 1.47
Factors influencing the immune response. 3. The blocking effect of Corynebacterium parvum upon the induction of acquired immunological unresponsiveness to bovine serum albumin in the adult rabbit. Clin Exp Immunol (1968) 1.46
Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol (1998) 1.41
Delayed molecular responses to brain irradiation. Int J Radiat Biol (1997) 1.39
[Corticoid treatment in Castleman's disease]. Med Clin (Barc) (1995) 1.39
Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer (1997) 1.39
Nuclear magnetic resonance studies of several experimental and human malignant tumors. Cancer Res (1973) 1.35
Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte-mediated cytolysis. J Exp Med (1979) 1.32
Adjuvant-induced antired blood cell activity in CBA mice. Clin Exp Immunol (1971) 1.31
T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol (2001) 1.28
Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res (1999) 1.28
The activation state of macrophage subpopulations from a murine fibrosarcoma. Int J Cancer (1980) 1.26
Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res (1999) 1.26
Influences of interleukins 2 and 4 on tumor necrosis factor production by murine mononuclear phagocytes. Cancer Res (1990) 1.25
A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther (1997) 1.25
Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol (1999) 1.24
Radiosensitivity of ataxia-telangiectasia, X-linked agammaglobulinemia, and related syndromes using a modified colony survival assay. Cancer Res (1994) 1.24
Production of interleukin-1 and tumor necrosis factor by human peripheral monocytes activated by periodontal bacteria and extracted lipopolysaccharides. J Dent Res (1988) 1.24
A new approach to the validation of tissue microarrays. J Pathol (2006) 1.23
Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res (1997) 1.22
Induction of acute phase gene expression by brain irradiation. Int J Radiat Oncol Biol Phys (1995) 1.20
Comparison of the gastrointestinal syndrome after total-body or total-abdominal irradiation. Radiat Res (1989) 1.18
Activation of the classical and alternate pathways of complement by Corynebacterium parvum. Clin Exp Immunol (1975) 1.18
Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology (2001) 1.16
A comparative study of anaerobic Coryneforms. Attempts to correlate their anti-tumour activity with their serological properties and ability to stimulate the lymphoreticular system. Immunology (1975) 1.16
Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr (1993) 1.15
The in vitro killing of syngeneic cells by peritoneal cells from adjuvant-stimulated mice. Cell Immunol (1975) 1.14
Properties of an antigenic polysaccharide from Corynebacterium parvum. J Bacteriol (1974) 1.14
Lymphocyte-activating factor. I. Generation and physicochemical characterization. J Immunol (1978) 1.12
Phenotype and functions of intratumoral macrophages. Biochim Biophys Acta (1986) 1.12
Murine cytomegalovirus is present in both chronic active and latent states in persistently infected mice. Virology (1994) 1.10
Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol (1998) 1.10
Ionizing radiation affects 26s proteasome function and associated molecular responses, even at low doses. Radiother Oncol (2001) 1.09
Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol (2010) 1.07
Whole body skeletal imaging with [18F]fluoride ion and PET. J Comput Assist Tomogr (1993) 1.07
Nuclear magnetic resonance studies of cancer. IV. Correlation of water content with tissue relaxation times. J Natl Cancer Inst (1974) 1.06
[Experimental orthopic liver transplant]. Rev Esp Enferm Apar Dig (1972) 1.06
Radiation-induced astrocytic and microglial responses in mouse brain. Radiother Oncol (1993) 1.06
Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr (1992) 1.05
Factors influencing the immune response. II. Effects of the physical state of the antigen and of lymphoreticular cell proliferation on the response to intraperitoneal injection of bovine serum albumin in rabbits. Clin Exp Immunol (1967) 1.05
Geography and host biogeography matter for understanding the phylogeography of a parasite. Mol Phylogenet Evol (2008) 1.05
The effect of single doses of radiation on mouse spinal cord. Int J Radiat Oncol Biol Phys (1992) 1.05
The proteasome in cancer biology and treatment. Radiat Res (2001) 1.04
Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther (2000) 1.04
Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion. Cancer (1986) 1.03
Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr Cancer (1999) 1.02
Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med (1998) 1.02
Generation of intestinal mucosal lymphocytes in SCID mice reconstituted with mature, thymus-derived T cells. J Immunol (1998) 1.01
Molecular pathways that modify tumor radiation response. Am J Clin Oncol (2001) 1.01
Cytokine cascades in late normal tissue radiation responses. Int J Radiat Oncol Biol Phys (1995) 1.00
Tumour necrosis factor production by IL-2-activated macrophages in vitro and in vivo. Immunology (1989) 1.00
Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. Mol Immunol (2000) 0.98